These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30021187)

  • 21. Temozolomide stability in extemporaneously compounded oral suspensions.
    Trissel LA; Zhang Y; Koontz SE
    Int J Pharm Compd; 2006; 10(5):396-9. PubMed ID: 23974320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stability of zonisamide in extemporaneously compounded oral suspensions.
    Abobo CV; Wei B; Liang D
    Am J Health Syst Pharm; 2009 Jun; 66(12):1105-9. PubMed ID: 19498126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stability of propylthiouracil in extemporaneously prepared oral suspensions at 4 and 25 degrees C.
    Nahata MC; Morosco RS; Trowbridge JM
    Am J Health Syst Pharm; 2000 Jun; 57(12):1141-3. PubMed ID: 10911513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stability of norfloxacin in an extemporaneously prepared oral liquid.
    Johnson CE; Price J; Hession JM
    Am J Health Syst Pharm; 2001 Apr; 58(7):577-9. PubMed ID: 11296605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naratriptan hydrochloride in extemporaneosly compounded oral suspensions.
    Zhang YP; Trissel LA; Fox JL
    Int J Pharm Compd; 2000; 4(1):69-71. PubMed ID: 23985892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stability of extemporaneous erlotinib, lapatinib, and imatinib oral suspensions.
    Li Q; Liu Z; Kolli S; Wetz K; Griffith N; Poi MJ
    Am J Health Syst Pharm; 2016 Sep; 73(17):1331-7. PubMed ID: 27543577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stability of ursodiol in an extemporaneously compounded oral liquid.
    Johnson CE; Nesbitt J
    Am J Health Syst Pharm; 1995 Aug; 52(16):1798-1800. PubMed ID: 8528836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stability of sumatriptan succinate in extemporaneously prepared oral liquids.
    Fish DN; Beall HD; Goodwin SD; Fox JL
    Am J Health Syst Pharm; 1997 Jul; 54(14):1619-22. PubMed ID: 9248606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stability of bethanechol chloride, pyrazinamide, quinidine sulfate, rifampin, and tetracycline hydrochloride in extemporaneously compounded oral liquids.
    Allen LV; Erickson MA
    Am J Health Syst Pharm; 1998 Sep; 55(17):1804-9. PubMed ID: 9775343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stability of ciprofloxacin in an extemporaneous oral liquid dosage form.
    Johnson CE; Wong DV; Hoppe HL; Bhatt-Mehta V
    Int J Pharm Compd; 1998; 2(4):314-7. PubMed ID: 23989641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of Extemporaneously Compounded Aripiprazole Oral Suspensions for Use in Children.
    Pramann LA; Davidow LW; van Haandel L; Funk RS
    Int J Pharm Compd; 2016; 20(3):257-261. PubMed ID: 28333668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stability of levofloxacin in an extemporaneously compounded oral liquid.
    VandenBussche HL; Johnson CE; Fontana EM; Meram JM
    Am J Health Syst Pharm; 1999 Nov; 56(22):2316-8. PubMed ID: 10582824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stability of alprazolam, chloroquine phosphate, cisapride, enalapril maleate, and hydralazine hydrochloride in extemporaneously compounded oral liquids.
    Allen LV; Erickson MA
    Am J Health Syst Pharm; 1998 Sep; 55(18):1915-20. PubMed ID: 9784772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids.
    Allen LV; Erickson MA
    Am J Health Syst Pharm; 1996 Sep; 53(17):2073-8. PubMed ID: 8870895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stability of ganciclovir in extemporaneously compounded oral liquids.
    Anaizi NH; Swenson CF; Dentinger PJ
    Am J Health Syst Pharm; 1999 Sep; 56(17):1738-41. PubMed ID: 10512505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Formulation and stability of an extemporaneously compounded oral solution of chlorpromazine HCl.
    Prohotsky DL; Juba KM; Zhao F
    J Pain Palliat Care Pharmacother; 2014 Dec; 28(4):367-70. PubMed ID: 25338106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stability of lamotrigine in two extemporaneously prepared oral suspensions at 4 and 25 degrees C.
    Nahata MC; Morosco RS; Hipple TF
    Am J Health Syst Pharm; 1999 Feb; 56(3):240-2. PubMed ID: 10030509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions.
    Kabiche D; Balde IB; Majoul E; Kabiche S; Bourguignon E; Fontan JE; Cisternino S; Schlatter J
    Int J Pharm Compd; 2017; 21(2):160-163. PubMed ID: 28346212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stability of extemporaneously compounded spironolactone suspensions.
    Mathur LK; Wickman A
    Am J Hosp Pharm; 1989 Oct; 46(10):2040-2. PubMed ID: 2816959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stability of ursodiol 25 mg/mL in an extemporaneously prepared oral liquid.
    Mallett MS; Hagan RL; Peters DA
    Am J Health Syst Pharm; 1997 Jun; 54(12):1401-4. PubMed ID: 9194984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.